香丹舒心胶囊联合阿托伐他汀钙片对心血瘀阻型冠心病患者左心室结构与功能的影响OA
Effects of Xiangdan Shuxin Capsule Combined with Atorvastatin Calcium Tablets on Left Ventricular Structure and Function in Patients with Coronary Heart Disease of Heart Blood Stasis Type
目的:探讨香丹舒心胶囊联合阿托伐他汀钙片治疗心血瘀阻型冠心病(CHD)患者的临床效果.方法:前瞻性选取2022年4月～2024年4月于本院接受诊治的100 例心血瘀阻型CHD患者作为研究对象,采用随机数字表法分为对照组和观察组,每组50 例.对照组口服阿托伐他汀钙片,观察组在对照组基础上口服香丹舒心胶囊,两组均治疗4周.比较两组患者中医证候积分、左心室结构及功能指标[左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)、二尖瓣血流舒张早期最大流速与舒张晚期最大流速比值(E/A)]、心肌损伤标志物[肌钙蛋白I(cTnI)、肌酸激酶(CK)]、血脂指标[低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)]、临床疗效及不良反应发生情况.结果:治疗后,两组各项中医证候积分、LVEDD、LVESD、cTnI、CK、LDL-C和TC均降低,且观察组低于对照组(P＜0.05);LVEF、E/A和HDL-C均升高,且观察组高于对照组(P＜0.05).观察组临床治疗总有效率(90.00%)高于对照组(74.00%,P＜0.05);不良反应总发生率(4.00%)低于对照组(18.00%,P＜0.05).结论:香丹舒心胶囊联合阿托伐他汀钙片可有效提高心血瘀阻型CHD患者临床疗效,改善临床症状、左心室结构及功能,降低血脂水平,减轻心肌损伤,且不增加不良反应的发生风险.
Objective:To explore the clinical effect of Xiangdan Shuxin Capsule combined with atorvastatin calcium tablets in the treatment of patients with coronary heart disease(CHD)of heart blood stasis type.Methods:Totally 100 patients with heart blood stasis type CHD who received diagnosis and treatment in the hospital from April 2022 to April 2024 were prospectively selected and divided into the control group and the observation group based on the random number table method,with 50 patients in each group.The control group received oral administration of atorvastatin calcium tablets,whereas the observation group was given Xiangdan Shuxin Capsule in addition to the treatment of the control group.Both groups were treated for 4 weeks.Traditional Chinese medicine(TCM)syndrome scores,left ventricular structure and function indexes[left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF),ratio of early to late diastolic peak flow velocities across the mitral valve(E/A)],myocardial injury markers[cardiac troponin I(cTnI),creatine kinase(CK)],blood lipid indexes[low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC),high-density lipoprotein cholesterol(HDL-C)],clinical efficacy and adverse reactions were compared between the two groups.Results:After treatment,the scores of various TCM syndromes,LVEDD,LVESD,cTnI,CK,LDL-C and TC were reduced in both groups,and the above indexes in the observation group were lower(P<0.05).LVEF,E/A and HDL-C were increased in both groups,and the observation group showed higher values(P<0.05).The total clinical effective rate of the observation group(90.00%)was higher than that of the control group(74.00%,P<0.05),and the overall incidence of adverse reactions(4.00%)was lower than that of the control group(18.00%,P<0.05).Conclusion:Xiangdan Shuxin Capsule combined with atorvastatin calcium tablets can effectively improve clinical efficacy in patients with CHD of heart blood stasis type,relieve clinical symptoms,optimize left ventricular structure and function,reduce blood lipid levels,and alleviate myocardial injury,without increasing the risk of adverse reactions.
高东升;王美阁;王正飞;刘晶梅;李瑜贤
北京中医药大学东直门医院洛阳医院心病科,洛阳 471000北京中医药大学东直门医院洛阳医院心病科,洛阳 471000北京中医药大学东直门医院洛阳医院心病科,洛阳 471000北京中医药大学东直门医院洛阳医院心病科,洛阳 471000北京中医药大学东直门医院洛阳医院心病科,洛阳 471000
医药卫生
冠心病心血瘀阻型香丹舒心胶囊左心室结构左心室功能
coronary heart diseaseheart blood stasis typeXiangdan Shuxin Capsuleleft ventricular structureleft ventricular function
《中国合理用药探索》 2026 (2)
44-50,7
评论